Monoclonal antibody / biologic infusion reaction
Cytokine-release and hypersensitivity reactions to biologics · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Reactions to therapeutic monoclonal antibodies include first-infusion cytokine-release reactions (fever, rigors, flushing, dyspnoea), IgE-mediated anaphylaxis (classically to the galactose-alpha-gal epitope on cetuximab) and delayed serum-sickness reactions. Distinguishing the mechanism directs rate adjustment, premedication or desensitisation.
Red flags
- Hypotension, stridor or wheeze
- Severe rigors with hypoxia
- Reaction to cetuximab (alpha-gal anaphylaxis risk)
- Delayed arthralgia, rash and fever (serum sickness)
- Signs of tumour lysis during rituximab
Assessment
Differential diagnosis
- Cytokine-release reaction (first infusion, non-IgE)
- IgE-mediated anaphylaxis (e.g. cetuximab/alpha-gal, chimeric antibodies)
- Serum sickness-like reaction (delayed)
- Tumour lysis-related symptoms (rituximab in bulky disease)
- Vasovagal reaction
Investigations
- Document timing, infusion number and symptom pattern
- Continuous monitoring during infusion
- Mast cell tryptase after severe reactions
- FBC and tumour lysis panel if rituximab in high tumour burden
- Specific IgE (e.g. alpha-gal for cetuximab) where relevant
Management
- Stop or slow the infusion at the first reaction and assess severity
- Treat airway/cardiovascular compromise as anaphylaxis with IM adrenaline
- Give antihistamine, corticosteroid, antipyretic and oxygen as indicated
- For mild cytokine-release reactions, restart at a reduced rate once settled
- Enhance premedication (antihistamine, paracetamol, corticosteroid) and slow the rate for subsequent infusions
- Investigate for IgE sensitisation after anaphylaxis and arrange desensitisation if the drug is essential
- Monitor for delayed serum-sickness reactions in the days after infusion
- Document mechanism and grade; liaise with the treating specialty
Drugs & doses
Adrenaline IM — 500 mcg (0.5 mL 1:1000) for anaphylaxis
Chlorphenamine — 10 mg IV/IM for cutaneous/systemic symptoms
Hydrocortisone — 100-200 mg IV for moderate-severe reactions
Paracetamol — 1 g IV/oral for fever and rigors
Pethidine — 25 mg IV for severe rigors (if required)
Salbutamol — 5 mg nebulised for bronchospasm
Disposition
Observe after mild reactions and continue with premedication; refer significant hypersensitivity to allergy and admit anaphylaxis for monitoring.
Complications & pitfalls
- Anaphylaxis
- Serum sickness
- Tumour lysis syndrome (rituximab)
- Interruption of essential biologic therapy
- Recurrent reactions despite premedication
Exam pearls
- First-infusion reactions are usually cytokine-release and respond to slowing the rate with premedication
- Cetuximab anaphylaxis is linked to pre-existing alpha-gal IgE and can occur on first exposure
- Delayed arthralgia, rash and fever suggest serum sickness, not immediate allergy
- Desensitisation allows continued use of an essential biologic after true hypersensitivity
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.